Arbutus Biopharma Corp - FORM 10-K - EX-10.46 - EXHIBIT 10.46 - March 13, 2015

Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - Arbutus Biopharma Corpexh_322.htm
EX-32.1 - EXHIBIT 32.1 - Arbutus Biopharma Corpexh_321.htm
EX-23.1 - EXHIBIT 23.1 - Arbutus Biopharma Corpexh_231.htm
EX-21.1 - EXHIBIT 21.1 - Arbutus Biopharma Corpexh_211.htm
EX-31.2 - EXHIBIT 31.2 - Arbutus Biopharma Corpexh_312.htm
EX-10.51 - EXHIBIT 10.51 - Arbutus Biopharma Corpexh_1051.htm
EX-10.50 - EXHIBIT 10.50 - Arbutus Biopharma Corpexh_1050.htm
EX-10.53 - EXHIBIT 10.53 - Arbutus Biopharma Corpexh_1053.htm
EX-10.54 - EXHIBIT 10.54 - Arbutus Biopharma Corpexh_1054.htm
EX-10.59 - EXHIBIT 10.59 - Arbutus Biopharma Corpexh_1059.htm
EX-10.44 - EXHIBIT 10.44 - Arbutus Biopharma Corpexh_1044.htm
EX-10.64 - EXHIBIT 10.64 - Arbutus Biopharma Corpexh_1064.htm
EX-10.73 - EXHIBIT 10.73 - Arbutus Biopharma Corpexh_1073.htm
EX-10.66 - EXHIBIT 10.66 - Arbutus Biopharma Corpexh_1066.htm
EX-10.65 - EXHIBIT 10.65 - Arbutus Biopharma Corpexh_1065.htm
EX-10.41 - EXHIBIT 10.41 - Arbutus Biopharma Corpexh_1041.htm
EX-10.70 - EXHIBIT 10.70 - Arbutus Biopharma Corpexh_1070.htm
EX-10.69 - EXHIBIT 10.69 - Arbutus Biopharma Corpexh_1069.htm
EX-10.47 - EXHIBIT 10.47 - Arbutus Biopharma Corpexh_1047.htm
EX-10.75 - EXHIBIT 10.75 - Arbutus Biopharma Corpexh_1075.htm
EX-10.40 - EXHIBIT 10.40 - Arbutus Biopharma Corpexh_1040.htm
EX-10.49 - EXHIBIT 10.49 - Arbutus Biopharma Corpexh_1049.htm
EX-10.71 - EXHIBIT 10.71 - Arbutus Biopharma Corpexh_1071.htm
EX-10.56 - EXHIBIT 10.56 - Arbutus Biopharma Corpexh_1056.htm
EX-10.76 - EXHIBIT 10.76 - Arbutus Biopharma Corpexh_1076.htm
EX-10.67 - EXHIBIT 10.67 - Arbutus Biopharma Corpexh_1067.htm
EX-10.52 - EXHIBIT 10.52 - Arbutus Biopharma Corpexh_1052.htm
EX-10.58 - EXHIBIT 10.58 - Arbutus Biopharma Corpexh_1058.htm
EX-10.62 - EXHIBIT 10.62 - Arbutus Biopharma Corpexh_1062.htm
EX-10.61 - EXHIBIT 10.61 - Arbutus Biopharma Corpexh_1061.htm
EX-10.63 - EXHIBIT 10.63 - Arbutus Biopharma Corpexh_1063.htm
EX-10.74 - EXHIBIT 10.74 - Arbutus Biopharma Corpexh_1074.htm
EX-10.77 - EXHIBIT 10.77 - Arbutus Biopharma Corpexh_1077.htm
EX-10.60 - EXHIBIT 10.60 - Arbutus Biopharma Corpexh_1060.htm
EX-10.45 - EXHIBIT 10.45 - Arbutus Biopharma Corpexh_1045.htm
EX-10.72 - EXHIBIT 10.72 - Arbutus Biopharma Corpexh_1072.htm
EX-10.55 - EXHIBIT 10.55 - Arbutus Biopharma Corpexh_1055.htm
EX-10.43 - EXHIBIT 10.43 - Arbutus Biopharma Corpexh_1043.htm
EX-10.39 - EXHIBIT 10.39 - Arbutus Biopharma Corpexh_1039.htm
EX-10.42 - EXHIBIT 10.42 - Arbutus Biopharma Corpexh_1042.htm
EX-10.48 - EXHIBIT 10.48 - Arbutus Biopharma Corpexh_1048.htm
EX-10.57 - EXHIBIT 10.57 - Arbutus Biopharma Corpexh_1057.htm
EXCEL - IDEA: XBRL DOCUMENT - Arbutus Biopharma CorpFinancial_Report.xls
10-K - FORM 10-K - Arbutus Biopharma Corpf10k_031215.htm
EX-31.1 - EXHIBIT 31.1 - Arbutus Biopharma Corpexh_311.htm
EX-10.68 - EXHIBIT 10.68 - Arbutus Biopharma Corpexh_1068.htm
Exhibit 10.46
 
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
 
AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
  
1. CONTRACT ID CODE
PAGE OF PAGES
            V 1 2
2. AMENDMENT/MODIFICATION NO
3. EFFECTIVE DATE
 4. REQUISITION/PURCHASE REQ. NO.  
5. PROJECT NO. (If applicable)
P00004
  
10/03/2011
see schedule
          
6. ISSUED BY
CODE
W911QY
7. ADMINISTERED BY (If other than item 6)
CODE
SCN01A
NATICK CONTRACTING DIVISION
64 Thomas Johnson Drive 
Frederick MD   21702-4300
DCMA AMERICAS (CANADA)
275 BANK ST.
SUITE 200
OTTAWA, ONT. CNK2P-2L6
 
     
                   
8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)
TEKMIRA PHARMACEUTICALS CORPORATION
 X
9A. AMENDMENT OF SOLICITATION NO.
8900 GLENLYON PKY SUITE 100
BURNABY V5J 5J8
  
9B. DATED (SEE ITEM 11)
 
  X
10A. MOD. OF CONTRACT/ORDER NO.
W9113M-10-C-0057
  X 10B. DATED (SEE ITEM 13)
CODE     49WU1
  
FACILITY CODE
  
Jul 14, 2010
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
o
The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer
  
o is extended      o is not extended.
 
Offer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods:
(a) By completing Items 8 and 15, and returning _____ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN
REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.
  
12. ACCOUNTING AND APPROPRIATION DATA (If required)
See SCHEDULE
    
                   
13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS.
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
 
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
                   
 
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).
X
C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
Mutual Agreement of Both Parties
 
D. OTHER (Specify type of modification and authority)
                   
E. IMPORTANT: Contractor      o is not,       x is required to sign this document and return        1       copies to the issuing office.
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
 
 
 
See Attached Summary of Changes.
 
 
 
 
Except as provided herein, all terms and conditions ofthe document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.
15A. NAME AND TITLE OF SIGNER (Type or print)
16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
 
  
15B. CONTRACTOR/OFFEROR
15C. DATE SIGNED
 16B. UNITED STATES OF AMERICA
16C. DATE SIGNED
                   
      Oct 4 2011 BY  5 Oct 11    
 
(Signature of person authorized to sign)
    
(Signature of Contracting Officer)
      
 
NSN 7540·01- 152-8070
PREVIOUS EDITION
UNUSABLE
30-105-04
STANDARD FORM 30 (Rev. 10-83)
Prescribed by GSA
FAR (48 CFR) 53.243
 
 
 
 
W9113M-10-C-0057
(soconnell24)
Page 2 of 2
 
SECTION SF 30 BLOCK 14 CONTINUATION PAGE
 
SUMMARY OF CHANGES
 
A. Pursuant to mutual agreement between both parties, the following changes are made to CLIN 0001 to add an additional study (Cytotoxicity in Vitro Study) to satisfy FDA questions regarding Tekmira's therapeutic candidate. Additionally, the issued by organization of this contract has changed as shown below. This modificatio11 incorporates, by reference, the Contractors change proposal dated 6 Sep 2011 thereby effecting these changes.
 
 
1. 
SECTION A - SOLICITATION/CONTRACT FORM
 
The total cost of this contract was increased by $40,418.57 from $34,747,879.00 to $34,788,297.57.
 
 
2. 
The 'issued by' organization has changed from 
USASMDC/ARSTRAT
SMDC-RDC-EB
64 THOMAS JOHNSON DRIVE
FREDERICK MD 21702-4300
 
to
 
NATICK CONTRACTING DIVISION
64 THOMAS JOHNSON DR
FREDERICK MD 21702-4300
 
 
 
 
3.
SECTION B - SUPPLIES OR SERVICES AND PRICES
 
The following changes are made to CLIN 0001
 
CLIN 0001
The target cost has increased by $[***]from $[***] to $[***] . The target profit/fee has increased by $[***] from $[***] to $[***].
The minimum profit fee has increased by $[***] from $[***] to $[***]. The maximum profit fee has increased by $[***] from $[***] to $[***].
The total cost of this line item has increased by $40,418.57 from $34,747,879.00 to $34,788,297.57
 
4.  The following is added to page 7 of the Contractor's SOW, dated 22 Mar 2010, Section J.
 
Attachment 1:
 
4.2.3.4  Other Studies
4.2.3.4.1.  Conduct cytotoxicity in vitro study and complete draft report.
 
B.   The parties hereto specifically agree that the changes effected by this modification constitute both the consideration and the equitable adjustment due under any clause of this contract resulting from 11- incorporation of the proposal.
 
C.   All other terms and conditions of this contract remain the same and in full force and effect. 
 
(End of Summary of Changes)
 
 
 

Stock widget

Investing forum

Arbutus Biopharma Corp Reports